合縱科技(300477.SZ):貴州雅友擬27億元投資建設年產30萬噸電池級磷酸鐵一體化整體項目
格隆匯3月21日丨合縱科技(300477.SZ)公佈,公司為了進一步加大對動力電池、儲能電池正極材料的投入,打造具有市場競爭力的磷酸鐵鋰材料產業鏈,力爭成為世界級電池正極材料供應商的戰略佈局,公司擬以控股孫公司貴州雅友作為投資項目主體,在甕安經濟開發區基礎工業園內建設年產30萬噸電池級磷酸鐵一體化整體項目(包括磷礦制酸、硫鐵礦制酸的磷酸鐵全產業鏈項目)。
項目用地1120畝,項目計劃分兩期建設,項目一期計劃建設年產10萬噸電池級磷酸鐵項目,項目二期計劃建設年產20萬噸電池級磷酸鐵項目及配套磷礦制酸、硫鐵礦制酸項目。投資規模約27億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.